COMMUNIQUÉS West-GlobeNewswire

Anathapindika Health’s Detoxifying Supplements Are Headed to Retailers in the US
03/10/2025
The Company’s Name Comes From Its Root Cause: to Provide Effective, Natural Solutions to Those Battling Health Issues. Soon, American Consumers Will Have Access to Those Solutions. Fort Lauderdale, FL, Oct. 03, 2025 ( [...]
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
03/10/2025
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its [...]
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
03/10/2025
WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
03/10/2025
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated [...]
Anathapindika Is Bringing Holistic Health to the US Through a Trio of Unconventional Nutraceutical Formulas
03/10/2025
Anthapindika Health’s Flagship Product Bundle Addresses Overall Health and Well-Being Through Comprehensive Detoxing and Cleansing Fort Lauderdale, FL, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Anathapindika Health has been [...]
Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting
03/10/2025
New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting The data will be the latest of many additions to EVX-01’s [...]
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
03/10/2025
Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead candidate, evorpacept, in HER2+ gastric cancer SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE [...]
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
03/10/2025
NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
03/10/2025
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- [...]
Merit Medical Systems to Announce Third Quarter 2025 Results on October 30, 2025
03/10/2025
SOUTH JORDAN, Utah, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial [...]
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
03/10/2025
BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has [...]
Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences’ XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis
03/10/2025
HORSHAM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- In recognition of Eczema Awareness Month , STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, [...]
Virbac : Déclaration d'actions et de droits de vote 09/2025
03/10/2025
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights 09/2025
03/10/2025
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Sienna Announces Third Quarter 2025 Results Release Date and Conference Call
03/10/2025
MARKHAM, Ontario, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) announced that it will report its 2025 third quarter results after market close on Thursday, [...]
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
03/10/2025
An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metrics OV329 matched or exceeded inhibition demonstrated by therapeutic doses of first- [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired [...]
Cartesian Therapeutics Announces New Employment Inducement Grant
03/10/2025
FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the [...]
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
03/10/2025
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants NEW YORK [...]

Pages